加州太平洋生物科学公司 PACB 深 沪
已收盘 10-17 16:00:00 美东时间
1.64
-0.120
-6.82%
华盛通- 最 高1.77
- 今 开1.73
- 成交量 714.14万股
- 最 低 1.63
- 昨 收 1.76
- 总市值 4.92亿
- 52周最高 2.72
- 市盈率 静 --
- 换手率 2.38%
- 52周最低 0.8511
- 委 比 19.60%
- 总股本 3.00亿
- 历史最高 53.69
- 量 比 0.66
- 振 幅 7.95%
- 历史最低 0.8511
- 每 手 1
- 风险率 2.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings, Inc. announced its Q4 2025 priorities, including advancing its lead compound LB-100, pursuing acquisitions of complementary oncology assets, and enhancing operational readiness. The company is in advanced negotiations for potential transactions aligned with its strategic goals.
10-16 12:00
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
PacBio announced advancements in its sequencing platforms, introducing the new SPRQ-Nx chemistry to significantly lower genome sequencing costs to under $300. This innovation aims to enhance accessibility for population genomics, clinical research, and production-scale environments by reducing operational waste and offering multiomic capabilities, including 5hmC detection for epigenetic studies and 21 CFR Part 11 compliance. These updates reflect...
10-14 10:05
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
PacBio's HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, led by KDCA and KNIH. The initiative aims to sequence over 1,000 Korean genomes to create a high-quality reference for the population and integrate it into the global Human Pangenome Reference Consortium (HPRC). This effort will enhance understanding of population-specific genetic variations, improve diagnostics, and advance p...
10-13 13:05
Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity
PacBio's Revio system will sequence up to 7,800 genomes and epigenomes for the National Institute on Aging’s Long Life Family Study (LLFS), aiming to uncover factors influencing healthy aging and longevity. The study, one of the largest of its kind, uses high-accuracy HiFi long-read sequencing to detect structural variants, methylation patterns, and haplotypes missed by short-read technologies. LLFS, a long-term, multi-center study, involves 5,43...
10-08 13:05
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
PacBio和seqWell扩大合作，分销LongPlex™多重套件，用于基因组测序。该套件提高效率，降低成本，适用于大规模研究。
10-07 13:05
Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-03 20:11
PacBio Enters High-Throughput Carrier Screening Market With Expanded PureTarget Kits For Inherited Conditions
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the high-throughput carrier screening market with a significantly expanded
09-22 21:10
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
PacBio has expanded its PureTarget portfolio to offer a single, scalable solution for inherited disease screening, leveraging HiFi sequencing to consolidate multiple assays. This addresses challenges in testing genes linked to conditions like fragile X syndrome and spinal muscular atrophy, reducing costs and improving access. The new panels cover all difficult tier 3 genes and are available in flexible formats, supporting up to 100,000 samples an...
09-22 13:05
EpiCypher Joins PacBio Compatible Program To Enhance Single-Molecule Chromatin Sequencing With CUTANA Hia5 Enzyme
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The
09-03 21:06
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
PacBio and EpiCypher have partnered to integrate EpiCypher’s CUTANA® Hia5 enzyme with PacBio’s Fiber-seq assays, enabling single-molecule chromatin fiber sequencing. This collaboration allows researchers to simultaneously measure chromatin accessibility, DNA methylation, and genetic variation, advancing rare disease and cancer research. The integrated workflow provides insights into gene regulation and genomic complexities, consolidating multiple...
09-03 13:05
